Table 2.
Patient Characteristics
| UPN | Age, Sex | Disease | CIPN Drugs | Symptom Duration (Months) |
Prior Treatments for CIPN |
|---|---|---|---|---|---|
| 1 | 59, F | Lung | Carboplatin, paclitaxel | 3 | Opioids, duloxetine |
| 2a | 42, F | Breast | Docetaxel | 12 | ADs, others |
| 3a | 76, F | Lymphoma | Cyclophosphamide, procarbazine | 24 | Gabapentin |
| 4 | 54, F | Breast | Paclitaxel, docetaxel | 78 | Gabapentin, opioids, pregabalin, others |
| 5 | 46, M | Myeloma | Thalidomide | 48 | Opioids, ADs |
| 6 | 56, M | Colon | Oxaliplatin, fluorouracil, leucovorin | 9 | Magnesium, opioids, ADs |
| 7 | 60, F | Breast | Adriamycin, paclitaxel | 30 | Opioids, ADs, pregabalin |
| 8 | 76, F | Lymphoma | Flavopiradol, bortezomib | 6 | Opioids, ADs |
| 9 | 67, F | Colon | Oxaliplatin | 24 | Opioids, ADs, pregabalin, gabapentin |
| 10 | 56, F | Breast | Taxanes | 48 | Opioids, ADs, gabapentin |
| 11 | 60, F | Breast | Taxanes | 96 | Opioids, carbamazepine |
| 12 | 53, M | Colon | FOLFOX + bevacizumab | 30 | Opioids, gabapentin, carbamazepine, duloxetine |
| 13 | 52, F | Hodgkins | MOPP | 5 | Opioids, duloxetine, carbamazepine |
| 14 | 62, F | Myeloma | Bortezomib + flavopiradol | 48 | Opioids, gabapentin, carbamazepine, duloxetine |
| 15 | 63, F | Breast | Docetaxel | 5 | Gabapentin |
| 16 | 75, F | Breast | Paclitaxel | 4 | Gabapentin |
| 17 | 40, M | Colon | FOLFOX | 3 | ADs, tramadol, venlafaxine |
| 18 | 59, F | Breast | Paclitaxel | 24 | Gabapentin |
UPN = unique patient number; FOLFOX = fluorouracil, oxaliplatin, leucovorin; MOPP = mechlorethamine, vincristine, prednisone, procarbazine; ADs = antidepressants.
a
Not evaluable patients. Patient no. 2 was never treated because of rapidly progressive disease immediately after enrollment. Patient no. 3 only completed two treatments because of transportation problems.